Skip to main navigation Skip to search Skip to main content

PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck

  • Lori J. Wirth*
  • , Shaker Dakhil
  • , Gabriela Kornek
  • , Rita Axelrod
  • , Douglas Adkins
  • , Shubham Pant
  • , Paul O'Brien
  • , Philip R. Debruyne
  • , Kelly S. Oliner
  • , Jun Dong
  • , Swami Murugappan
    • *Corresponding author for this work
  • Massachusetts General Hospital
  • Cancer Center of Kansas
  • University of Vienna
  • Thomas Jefferson University
  • Washington University St. Louis
  • University of Oklahoma
  • Medical University of South Carolina
  • AZ Groeninge
  • Anglia Ruskin University
  • Amgen Incorporated

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck'. Together they form a unique fingerprint.
Sort by

Neuroscience

Immunology and Microbiology

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science